奥氮平治疗迟发性运动障碍。 （注：你原文中的“Oxiperomide”可能有误，推测这里应该是“Olanzapine”，我按照正确的词翻译了，如果不是，请根据实际情况调整 ）
Oxiperomide in tardive dyskinesia.
作者信息
Casey D E, Gerlach J
出版信息
J Neurol Neurosurg Psychiatry. 1980 Mar;43(3):264-7. doi: 10.1136/jnnp.43.3.264.
Tardive dyskinesia can be suppressed by dopaminergic receptor blockers, but often at the cost of a reciprocal increase in Parkinsonism. Oxiperomide, a dopaminergic antagonist that has been shown to reduce levodopa-induced dyskinesias without producing an equal aggravation of Parkinsonism, was evaluated in a blind placebo-controlled trial in 10 patients with tardive dyskinesia. It decreased tardive dyskinesia significantly (p less than 0.01) without significantly provoking or increasing Parkinsonism. There was no relationship between either tardive dyskinesia or Parkinsonism and eye blinking rates. These results can be interpreted as additional evidence for the existence of more than one population of dopamine receptors involved in controlling extrapyramidal function. Although oxiperomide is only a palliative suppressing agent in tardive dyskinesia, as the symptoms returned when the drug was stopped, it is an interesting agent in the search for selective dopaminergic receptor blockers.
迟发性运动障碍可被多巴胺能受体阻滞剂抑制，但往往以帕金森症相应加重为代价。奥昔哌醇是一种多巴胺能拮抗剂，已被证明可减少左旋多巴诱发的运动障碍，且不会同等程度地加重帕金森症。在一项针对10例迟发性运动障碍患者的双盲安慰剂对照试验中，对奥昔哌醇进行了评估。它能显著降低迟发性运动障碍（p小于0.01），且不会显著引发或加重帕金森症。迟发性运动障碍或帕金森症与眨眼频率之间均无关联。这些结果可被解释为存在不止一种参与控制锥体外系功能的多巴胺受体群体的额外证据。尽管奥昔哌醇在迟发性运动障碍中只是一种缓解性抑制药物，因为停药后症状会复发，但它在寻找选择性多巴胺能受体阻滞剂方面是一种有趣的药物。
Zotero 插件